6:01AM Compugen announces results showing its CGEN-15001T drug may have potential for cancer immunotherapy (CGEN) 5.30 : Co announced results demonstrating the therapeutic potential of CGEN-15001T as a drug target for treatment of multiple cancers by means of monoclonal antibody ("mAb") therapy. These results indicate that CGEN-15001T is expressed on numerous types of cancer, such as carcinomas, sarcomas, melanoma and hematological cancers as well as on immune cells. These findings, together with previous results supporting its active immunomodulatory effect, 'strongly support CGEN-15001T's potential as a powerful drug target for treatment of various solid and hematological cancers, an area of great interest to the pharmaceutical industry.'
Recent CGEN News
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 05/18/2026 08:02:35 PM
- Compugen surges after revenue tops forecasts despite quarterly loss miss (CGEN) • IH Market News • 05/18/2026 12:35:18 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/18/2026 11:00:20 AM
- Compugen Reports First Quarter 2026 Results • PR Newswire (US) • 05/18/2026 11:00:00 AM
- Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum • PR Newswire (US) • 05/12/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 08:03:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 08:02:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/27/2026 10:52:43 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/27/2026 10:40:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/15/2026 08:10:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/15/2026 08:07:11 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 04/15/2026 08:03:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/15/2026 10:38:12 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/15/2026 10:16:38 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/13/2026 11:28:42 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 08:05:10 PM
- Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference • PR Newswire (US) • 04/09/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 11:31:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 11:29:40 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/02/2026 02:06:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/30/2026 10:04:03 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/26/2026 02:42:06 PM

